Your world doesn’t stand still and neither do we. For nearly 25 years, JB Ashtin has helped clients navigate scientific advances, regulatory shifts, and evolving expectations. We come alongside as strategic partners, quick learners, and thoughtful listeners who bring clarity and calm to complex work.
More than 90% of our business annually comes from referrals or repeat clients, and we take that trust seriously. Relationships often begin with a single project and grow into long-term collaborations grounded in mutual respect, purpose, and a shared commitment to improving lives.
We’re built for biotech startups and small-to-mid-size pharmaceutical companies that need high-touch support with serious scientific rigor. We also proudly serve large pharmaceutical clients—trusted partnerships that have lasted more than a decade. Whether you’re preparing for Phase 2/3 data, launching a product, or communicating complex results across internal and external audiences, we act as an extension of your team to help you move science forward with confidence.
Whether you’re working in a common condition or a niche space, we’ve likely worked with teams like yours. Our experience spans:
Reaching specialists and building awareness takes precision and persistence. Our rare disease clients trust us to help identify therapy area experts, create targeted education, and navigate the nuances of uncommon conditions.
- Angelman syndrome
- Autoimmune pulmonary alveolar proteinosis
- Canavan disease
- Congenital athymia
- Duchenne’s muscular dystrophy
- Hemophilia B
- Hypoparathyroidism
- Farber disease
- Focal segmental glomerulosclerosis
- Friedreich’s ataxia
- Growth hormone deficiency
- Molybdenum cofactor deficiency Type A
- Myotonic dystrophy
- Neurogenic orthostatic hypotension
- Paroxysmal nocturnal hemoglobinuria
- Phelan-McDermid syndrome
- Pitt Hopkins syndrome
- Spinal muscular atrophy
Creating a Network of Influencers who treat an ultra rare disease
A biopharmaceutical company developing an innovative treatment for an ultra-rare disease faced a common problem: very few known clinical and operational experts and a limited budget for outreach. They needed a strategic approach to identify and engage the right HCP stakeholders—but didn’t know where to begin.
To expand early engagement, the client partnered with JB Ashtin to build a targeted influencer map across all 50 states. Acting as an extension of their internal team, we developed a custom database of immunologists and newborn screening influencers, state by state. These experts often serve as gatekeepers for newly diagnosed patients and are crucial to early awareness-building efforts.
Our team continuously updated the database, tracked turnover among key HCPs, and helped the client foster meaningful relationships aligned with their clinical development plan and future educational goals.
The client gained a strategic roadmap for outreach, a living network of verified HCP influencers, and a deeper insight into how newborn screening is handled across regions. This foundation has strengthened stakeholder engagement and informed upcoming clinical and educational initiatives.
Using Immersive Virtual Reality to Deliver Disease State Education
Preparing to launch a new ADHD treatment, a mid-sized pharma client needed to shift perceptions among psychiatrists who doubted that ADHD persists into adulthood. Without changing minds, the product risked being unfairly dismissed despite compelling evidence.
To support HCP education and raise awareness, JB Ashtin designed an immersive “day-in-the-life” VR experience. Our goal was to help providers understand adult ADHD from a first-person perspective. Shot in 360° surround video, the experience allowed users to witness the challenges faced by undiagnosed adults in various life domains—home, work, and social.
We collaborated with the client’s legal and regulatory teams to ensure compliance and created flexible viewing options for congresses, rep visits, and digital platforms.
The program debuted at 2 national congresses, with more than 600 HCPs participating. Feedback was overwhelmingly positive, prompting the client to expand its use in field engagement. HCPs reported greater empathy, better understanding, and a greater willingness to consider adult ADHD in clinical practice.
Staying Top of Mind with HCPs Without New Data
With no new clinical data in 2 years, a small pharmaceutical company needed to maintain HCP engagement with their brand. Standard tactics were falling flat. They needed something fresh, authentic, and compliant.
JB Ashtin proposed a video series featuring real, unscripted conversations among respected KOLs. Instead of traditional slide decks, we created a studio-recorded series of expert discussions on the disorder, treatment approaches, and common clinical challenges.
We worked closely with client stakeholders to align on messaging, mitigate compliance risks, and coach speakers ahead of production. The result was a dynamic, cross-channel campaign that brought the therapy back into focus.
The first videos were launched on the client’s website to enthusiastic feedback. The sales team successfully used the campaign to support in-practice conversations and keep the product top of mind.
Accelerate Recruiting for Ambitious Clinical Study/Strict Enrollment Criteria
One of the largest psychiatric clinical trials in US history was falling behind on recruitment. With strict eligibility criteria and a mid-trial pivot to a new patient type, the sponsor faced a real risk of delay. The client needed to reenergize study coordinators, who are on the front lines of study recruitment.
JB Ashtin designed and executed a high-impact conference specifically for study coordinators, focusing entirely on their experience (not the investigators). The event highlighted the importance of the trial, featured a live patient interview, and offered valuable peer discussions and networking opportunities.
We also introduced awards to recognize top recruiters and reinforced a sense of shared mission across trial sites.
Coordinator feedback was overwhelmingly positive. Engagement soared, and so did enrollment. Energized and aligned, the sites met their recruitment goals faster than anticipated, keeping the trial on track.